Gilead Sciences (FRA:GIS) Net Issuance of Debt : €-253 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Gilead Sciences Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Gilead Sciences's net issuance of debt for the three months ended in Mar. 2024 was €0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was €-253 Mil.

Gilead Sciences Net Issuance of Debt Historical Data

The historical data trend for Gilead Sciences's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Net Issuance of Debt Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

-2,475.00

4,672.25

-4,203.75

-1,416.00

-247.59

Gilead Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-253.93	0.92	-

Gilead Sciences Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-253 Mil.

Gilead Sciences Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (FRA:GIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (FRA:GIS) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.